Valneva SE (VALN)

AI Score

Unlock

6.99

0.24 (3.56%)

At close: Mar 03, 2025, 3:44 PM

No 1D chart data available

Bid	6.7
Market Cap	567.92M
Revenue (ttm)	97.86M
Net Income (ttm)	-4.58M
EPS (ttm)	-0.13
PE Ratio (ttm)	-53.8
Forward PE	-8.24
Analyst	Buy

Ask	7.08
Volume	31,717
Avg. Volume (20D)	64,703
Open	6.88
Previous Close	6.75
Day's Range	6.78 - 7.19
52-Week Range	3.62 - 9.50
Beta	1.11

About VALN

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile tox...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 5, 2021

Employees 676

Stock Exchange NASDAQ

Ticker Symbol VALN

Website https://valneva.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for VALN stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 143.06% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Valneva SE is scheduled to release its earnings on Mar 20, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription